Highly anticipated trial results expected soon could move all three of these biotechs

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Esperion Therapeutics, Inc.(NASDAQ:ESPR), and Loxo Oncology, Inc. (NASDAQ:LOXO) are all scheduled to present highly anticipated trial results in September that could boost expectations for their experimental therapies. Here's what could go right or wrong in the weeks ahead.